Showing 161 - 180 results of 193 for search '"cancer immunotherapy"', query time: 0.06s Refine Results
  1. 161

    Oncolytic peptide LTX-315 induces anti-pancreatic cancer immunity by targeting the ATP11B-PD-L1 axis by Meng Wang, Xing Huang, Tingbo Liang, Tianyu Tang, Gang Zhang, Minghao Lu, Zhengtao Hong, Junming Huang, Xiao Zhi

    Published 2022-03-01
    “…Therefore, LTX-315, or the development of ATP11B-targeting drugs, might improve the efficacy of cancer immunotherapy.…”
    Get full text
    Article
  2. 162

    Ly6E on tumor cells impairs anti-tumor T-cell responses: a novel mechanism of tumor-induced immune exclusion by Lan Hailin, Chen Yiting, Wu Yue, Li Lijun, Zhang Renlu, Chen Yunhan, Zhu Yanyang, Zhang Qiuyu

    Published 2024-11-01
    “…Conclusion Our study illuminated that Ly6E-expressing tumor cells facilitated the accumulation of M2 macrophages in TME, which contributes to CD8+ T cell exclusion and provides new insights for improving efficacy of cancer immunotherapy.…”
    Get full text
    Article
  3. 163
  4. 164
  5. 165
  6. 166

    Efficacy of natural killer T and gammadelta T cells in mesothelin-targeted immunotherapy of pancreatic cancer by Yuankui Zhu, Yaxi Yang, Linghe Yue, Lei Wan, Xuqian Ma, Qing Yang, Xuan Tian, Yuguan Li, Ke Wang, Shaozhong Wei, Shaozhong Wei, Shaozhong Wei, Dianbao Zuo, Mingqian Feng, Mingqian Feng

    Published 2025-02-01
    “…Current pancreatic cancer immunotherapy focused on alphabeta (αβ) T cells, either through CD3-engaged bispecific antibodies or CAR-T. …”
    Get full text
    Article
  7. 167
  8. 168

    Peripheral blood cell counts as predictors of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis by Xinyu Zhang, Bei Zhang, Danfei Li, Yunchao Yang, Sen Lin, Ruiqi Zhao, Yijia Li, Lisheng Peng

    Published 2025-01-01
    “…Predicting and preventing irAEs during the early stages of treatment has become a critical research focus in cancer immunotherapy. This study aims to evaluate the predictive value of peripheral blood cell counts for irAEs.MethodsStudies meeting the inclusion criteria were identified through database searches. …”
    Get full text
    Article
  9. 169

    RNA N6‐Methyladenosine‐Binding Protein YTHDFs Redundantly Attenuate Cancer Immunity by Downregulating IFN‐γ Signaling in Gastric Cancer by Dongjun Jang, Chanwoong Hwa, Seoyeon Kim, Jaeik Oh, Seungjae Shin, Soo‐Jin Lee, Jiwon Kim, Sang Eun Lee, Yoojin Yang, Dohee Kim, Seoho Lee, Hae Rim Jung, Yumi Oh, Kyunggon Kim, Hye Seung Lee, Joon‐Yong An, Sung‐Yup Cho

    Published 2025-01-01
    “…Collectively, these findings highlight how YTHDFs modulate cancer immunity by influencing IFN‐γ signaling through IRF1 regulation, suggesting their viability as therapeutic targets in cancer immunotherapy.…”
    Get full text
    Article
  10. 170

    Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus... by Dong-Sup Lee, Mi-Ju Park, Namhee Lee, Yun-Hui Jeon, Jiyoon Yoo, Suk-kyung Shin, Songyi Lee, Byung-Jin Jung, Yun-Kyoung Hong, Keunhee Oh

    Published 2023-01-01
    “…Background Oncolytic virus immunotherapy has revolutionized cancer immunotherapy by efficiently inducing both oncolysis and systemic immune activation. …”
    Get full text
    Article
  11. 171
  12. 172

    Resveratrol contributes to NK cell-mediated breast cancer cytotoxicity by upregulating ULBP2 through miR-17-5p downmodulation and activation of MINK1/JNK/c-Jun signaling by Bisha Ding, Jie Li, Jia-Lin Yan, Chun-Yan Jiang, Ling-Bo Qian, Jie Pan

    Published 2025-02-01
    “…This finding identifies RES as a potentially effective therapeutic agent for inhibiting BC progression and optimizing NK cell-based cancer immunotherapy.…”
    Get full text
    Article
  13. 173

    Machine-Learning Parsimonious Prediction Model for Diagnostic Screening of Severe Hematological Adverse Events in Cancer Patients Treated with PD-1/PD-L1 Inhibitors: Retrospective... by Seok Jun Park, Seungwon Yang, Suhyun Lee, Sung Hwan Joo, Taemin Park, Dong Hyun Kim, Hyeonji Kim, Soyun Park, Jung-Tae Kim, Won Gun Kwack, Sung Wook Kang, Yun-Kyoung Song, Jae Myung Cha, Sang Youl Rhee, Eun Kyoung Chung

    Published 2025-01-01
    “…Our model might enhance early diagnostic screening of irHAEs induced by PD-1/PD-L1 inhibitors, contributing to minimizing the risk of severe irHAEs and improving the effectiveness of cancer immunotherapy.…”
    Get full text
    Article
  14. 174

    Deregulated methylation and expression of PCDHGB7 in patients with non-small cell lung cancer: a novel prognostic and immunological biomarker by Yue Yuan, Yue Yuan, Xin Nie, Jiayi Gao, Jiayi Gao, Yumeng Tian, Yumeng Tian, Liuer He, Liuer He, Xue Wang, Ping Zhang, Junling Ma, Lin Li, Lin Li

    Published 2025-01-01
    “…Its function in lung cancer has not been elucidated.MethodsWe comprehensively investigated PCDHGB7 expression, prognosis, biological function, methylation patterns, and it’s relationship with immune infiltration and immunotherapy response through public datasets (HPA, TCGA, GEO, OncoDB and MEXPRESS). Two lung cancer immunotherapy cohorts from our clinical center were enrolled to detect the relationship between methylation and protein levels of PCDHGB7 in plasma and immunotherapy outcomes.ResultsPCDHGB7 expression was downregulated in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) and associated with tumor prognosis. …”
    Get full text
    Article
  15. 175

    Immunogenic dying cells elicit potent anti-tumor T cell immunity against lung metastasis and tumorigenesis by Min Hu, Xinyu Meng, Tong Wang, Yifan Wang, Xiaodong Chen, Dongliang Xu, Wei He, Hongjia Zhang, Wenzheng Guo, Bo Jing, Siwei Zhang, Jianhua Xu, Beibei Sun, Xueqian Sun, Tingting Liu, Na Ni, Tongtong Zhang, Wenwen Cui, Xiaoyu Wu, Liping Xia, Feng Yao, Fang Zhang, Jing Du, Jiong Deng

    Published 2025-01-01
    “…Conclusion Immunization with the ICD dying tumor cells evokes potent tumor-specific T cell immunity, which provides a novel approach for cancer immunotherapy.…”
    Get full text
    Article
  16. 176
  17. 177

    Arginase-1-specific T cells target and modulate tumor-associated macrophages by Mads Hald Andersen, Inés Lecoq, Ayako Wakatsuki Pedersen, Evelina Martinenaite, Shamaila Munir Ahmad, Maria Perez-Penco, Lucia Lara de la Torre, Marion Chapellier, Lars Rønn Olsen, Mia Aaboe-Jørgensen, Hannah Jorinde Glöckner, Anne Mette Askehøj Rømer

    Published 2025-01-01
    “…Background Arginase-1 (Arg1) expressing tumor-associated macrophages (TAMs) may create an immune-suppressive tumor microenvironment (TME), which is a significant challenge for cancer immunotherapy. We previously reported the existence of Arg1-specific memory T cells among peripheral blood mononuclear cells (PBMCs) and described that Arg-1-based immune modulatory vaccines (IMVs) control tumor growth and alter the M1/M2 macrophage ratio in murine models of cancer. …”
    Get full text
    Article
  18. 178
  19. 179
  20. 180